Skip to main content
. Author manuscript; available in PMC: 2017 Sep 22.
Published in final edited form as: J Mol Cell Cardiol. 2016 Sep 10;99:197–206. doi: 10.1016/j.yjmcc.2016.09.004

Fig. 6.

Fig. 6

Acute gene transfer of full length wtMYBPC3 in early cardiac directed differentiation prevents sarcomere disarray and cellular hypertrophy. a, AdMYBPC3 (250 moi) was applied to restore levels of cMyBP-C 12 after initiation of cardiac-directed differentiation. b, Full length cMyBP-C expression in hESC-CMs shown by M2-FLAG immunolocalization. c, Virus-delivered cMyBP-C localized correctly to each half of the sarcomeric A-band (~1.6 μm). d, AdMYBPC3 gene transfer prevented sarcomere disarray in HCM hESC-CMs, indicated in the picture as well as in the FFT analysis (regularity index = 0.09 ± 0.015, n = 10 vs. 0.13 ± 0.018, n = 9 after virus treatment, student t-test, *P = 0.0002). e, AdMYBPC3 gene transfer prevents CM hypertrophy compared to untreated UM38-2 PGD-HCM CMs (no treatment cell size = 4828.71 ± 3452.21 μm2, n = 193 vs. AdMYBPC3-treated cell size = 2888.83 ± 2047.93 μm2, n = 209). AdMYBPC3 gene transfer had no effect on UM22-2 CMs size (no treatment cell size = 2813.24 ± 1737.63 μm2, n = 211 vs. AdMYBPC3-treated cell size = 2744.38 ± 1639.60 μm2, n = 305). ***indicates significant difference from all other means, One-way ANOVA, Tukey’s multiple comparison test, p < 0.0001. Data were expressed as mean ± standard deviation.